Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Monoclonal antibody (MoAb) imaging has contributed greatly to the diagnosis and staging of both colorectal and ovarian cancers, and recently has been tested in patients with prostate cancer. Anatomic imaging modalities such as computed tomography, ultrasound, and magnetic resonance imaging have deficiencies in imaging each of these cancers that can be complemented or overcome by using radioimmunoscintigraphy. The management of patients with colorectal cancer, in particular, has been aided by developments in immunoscintigraphy. The new, safe, and easy-to-prepare MoAbs make possible an effective form of colon and rectal cancer imaging that has been used for (1) staging primary colorectal tumors in presurgical patients, (2) determining extent of disease, (3) continuing surveillance of patients at risk for recurrence of disease, (4) managing patients with elevated carcinoembryonic antigen levels (even those with otherwise negative workup results), and (5) imaging for occult, disease in patients both before and after surgery. In ovarian cancer patients, MoAbs are promising as safe, sensitive imaging tools. The U.S. Food and Drug Administration has approved 111In satumomab pendetide (OncoScint CR/OV; Cytogen Corporation, Princeton, NJ) for use in imaging colorectal and ovarian cancer. Immunoscintigraphy is being refined and tested to locate bony and soft-tissue metastases in patients with prostate cancer. As both a complementary tool and, in some cases, the imaging modality of choice, MoAbs have proven to be safe, accurate imaging tools for many patients with cancer.
 ...
PMID:Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer. 781

A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunoscintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extra-hepatic disease was significantly higher than that of cross-sectional radiological imaging (87% and 83% vs 44% and 53% respectively) with equal specificity of 74%. Scintigraphy identified 14 (36%) of 39 extra-hepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26%) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93% vs 28%). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extra-hepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.
 ...
PMID:Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. 1045 76